A T cell-based Ubiquitin-mediated mRNA Vaccine Provides Cross-Protection Against H1N1 and B Influenza Viruses in Mice

Highlights

  • •
    A novel mRNA vaccine was developed to achieve broad-spectrum protection against Influenza virus.
  • •
    The Ub-Re-N mRNA vaccine boosts CD8+ T cell immunity through ubiquitination modification.
  • •
    Vaccinated mice had significant reduced lung damage, viral load, and cytokine levels after influenza virus challenge.
  • •
    The vaccine demonstrates potential for broad-spectrum protection against H1N1 and B influenza viruses.


Abstract

Given the persistent antigenic drift of seasonal influenza viruses and the continuous threat of emerging pandemics, there is an urgent necessity to develop novel influenza vaccines capable of conferring broad-spectrum immunity against multiple viral subtypes. CD8+ T cells provide a promising approach to achieving such protection because of their ability to recognize conserved internal antigens. Particularly, the highly cross-reactive internal nucleoprotein of influenza virus demonstrates remarkable efficacy in safeguarding against infection caused by diverse strains. Ubiquitination modification is critical for the differentiation and functionality of CD8+ T cells, thereby modulating the immune response. In this study, three mRNA vaccines were designed using the influenza virus nucleoprotein as an immunogen, including wild-type N protein (WT-N), ubiquitinated wild N protein (Ub-WT-N), and ubiquitinated rearrangement N protein (Ub-Re-N). After immunizing C57BL/6 mice, both WT-N and Ub-WT-N vaccines elicited antibody production, while the Ub-Re-N group exhibited enhanced cellular immune response without inducing antibody production. Subsequently challenged with influenza viruses, the vaccinated mice showed significant protection against mortality and weight loss caused by H1N1 and influenza B strains. Notably, depletion of CD8+ T cells led to a substantial reduction in the protective efficacy of the Ub-Re-N vaccine. In conclusion, the mRNA vaccine encoding Ub-Re-N confers potent defense against influenza virus infection through induction of a robust antigen-specific T cell response.

Open access (free article). Read more at:
https://www.sciencedirect.com/science/article/pii/S266651742500118X



Popular posts from this blog

David M. Ojcius, PhD - Editorial Board - Journals | Elsevier

Image
David Ojcius is Professor at the University of the Pacific in San Francisco, USA. He gained his Ph.D. from the University of California, Berkeley, and did research at Rockefeller and Harvard before moving to the Pasteur Institute in Paris, France, where he worked for thirteen years. His research interests include viruses and intracellular bacteria, interactions with the innate immune system, microbiota, biochemistry and cell biology of infected cells, inflammation and aging. https://www.journals.elsevier.com/current-research-in-microbial-sciences/editorial-board/david-m-ojcius-phd
Read more

Dugoni faculty member will fight oral cancer with $700K NIH award

Image
Xiaoyuan Han, an assistant professor in the Arthur A. Dugoni School of Dentistry at University of the Pacific, has received a prestigious National Institutes of Health grant for $702,000 to study oral cancer using artificial intelligence tools. Han, who teaches in the Department of Biomedical Sciences, was awarded a Support for Research Excellence-First Independent Research Award for four years. “Dr. Han’s work could help identify patients needing early care and increase our ability to provide personalized medical care to treat these patients,” said David Ojcius, assistant dean for research and co-chair of the Department of Biomedical Sciences. The award will provide opportunities for predental and predoctoral dental students to participate in research and collaborate with a multidisciplinary team to improve oral pathology diagnosis, Han said.
Read more